# CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.

> **NCT06733610** · PHASE1 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 15 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia
- CD19/BCMA CAR T-cells
- Universal Allogeneic CAR T-cells

## Interventions

- **BIOLOGICAL:** universal allogeneic anti-CD19/BCMA CAR T-cells

## Key facts

- **NCT ID:** NCT06733610
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-05
- **Primary completion:** 2026-02-05
- **Final completion:** 2026-12-05
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06733610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06733610, "CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06733610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*